| Name | Title | Contact Details |
|---|
Novara Tesija Michela and Priehs is a Southfield, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Quellis was founded to deliver best-in-class therapies to patients suffering serious rare diseases – and underserved by current treatment options. The Company is based in Boston, and is led by partners from the biotech incubator Viridian LLC in collaboration with team at biotech accelerator Xontogeny LLC, and with funding from the Perceptive Xontogeny Venture Fund. The Quellis team has deep experience in mAb discovery and development, company creation, and private and public biotech investment. Our shared goal is to create meaningful medicines for every disease we target.
Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead compounds, cabozantinib and cobimetinib, tells the story of our evolution as a company. Each of these compounds were discovered in our own laboratories and advanced by us into clinical development. In addition, we have leveraged our earlier stage drug discovery and development capabilities to establish multiple partnerships and collaborations with leading pharmaceutical and biopharmaceutical partners. These alliances are designed to advance the development of multiple Exelixis-discovered therapies, and allow Exelixis to focus on maximizing the potential of cabozantinib. Exelixis has worldwide rights to cabozantinib, which we believe could have the potential to treat a wide variety of cancers. Cabozantinib received its initial regulatory approval for a single indication in 2012, and is marketed for that indication under the trade name COMETRIQ®. Cabozantinib is also the subject of a broad, global clinical development program that includes approximately 45 ongoing or planned clinical trials. Exelixis is the sponsor of two active global, randomized phase 3 pivotal trials: the METEOR trial in metastatic renal cell carcinoma, for which positive top-line results were announced in July 2015, and the CELESTIAL trial in advanced hepatocellular carcinoma. Founded and incorporated in 1994, Exelixis is headquartered in South San Francisco, California. We are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer.
Madeira Therapeutics is a Overland Park, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Clinical trials are designed around endpoints, but its the beginning that sets them up for success—including selecting the best RTSM partner for continuous and flexible support throughout the duration of a trial. With decades of experience, Endpoint Clinical is obsessed with proactive problem-solving, ensuring that issues are anticipated and resolved before they escalate, and any changes are easily incorporated. From day one, we become an extension of your team, seamlessly integrating into your trial operations. We minimize friction, reduce risk, and enable your clinical teams to focus where it matters most—on trial success. Endpoint is headquartered in Raleigh, NC, with offices across the US, EU, and Asia.